Cargando…

Brain and bone marrow metastases from rectal cancer

Despite the development of new treatment options based on the molecular characterization of colorectal cancer, 20% of patients present de novo metastatic disease, whereas 30-40% of patients who receive curative treatment relapse during follow up. Herein, we report 2 cases with rectal cancer that dev...

Descripción completa

Detalles Bibliográficos
Autores principales: Thomopoulou, Konstantina, Manolakou, Stavroula, Messaritakis, Ippokratis, Tzardi, Maria, Lagoudaki, Eleni, Koutsopoulos, Anastasios, Koulouris, Andreas, Kanellis, George, Kalbakis, Konstantinos, Mavroudis, Dimitris, Souglakos, Ioannis
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hellenic Society of Gastroenterology 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6928473/
https://www.ncbi.nlm.nih.gov/pubmed/31892804
http://dx.doi.org/10.20524/aog.2019.0423
Descripción
Sumario:Despite the development of new treatment options based on the molecular characterization of colorectal cancer, 20% of patients present de novo metastatic disease, whereas 30-40% of patients who receive curative treatment relapse during follow up. Herein, we report 2 cases with rectal cancer that developed uncommon sites of metastasis; the first patient had an isolated breast metastasis, while the second patient developed bone marrow infiltration with synchronous brain metastases. In order to evaluate the uncommon metastatic pattern of rectal cancer, we detected and enumerated circulating tumor cells (CTCs) using both immunofluorescence and real-time reverse transcriptase polymerase chain reaction in these patients’ peripheral blood. The procedure revealed the presence of CTCs, positive for CEACAM5 but negative for epithelial phenotype (EpCAM-), that might explain the patients’ metastatic potential and survival.